Deal Snapshot
Schrödinger Acquires XTAL BioStructures to Expand Drug Discovery Solutions in Pharmaceutical and Biotechnology Industries
Thursday 20 January 2022

New York-based life sciences and materials science company Schrödinger, Inc. (NASDAQ: SDGR) has acquired Boston-based structural biology services provider XTAL BioStructures, Inc. to expand Schrödinger's position in structure-based drug discovery, the company said.

Schrödinger and XTAL BioStructures closed the USD 6m all-cash acquisition on January 14, 2022, and XTAL BioStructures is now operating as part of Schrödinger.

Date Published: 20/01/2022